Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Patent
1994-03-24
1996-09-10
Cunningham, Thomas M.
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
530300, 530327, 530828, 4241851, 4242771, C07K 700, A61K 3808
Patent
active
055547249
ABSTRACT:
The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5462871 (1995-10-01), Boon-Falleur et al.
patent: 5487974 (1996-01-01), Boon-Falleur et al.
Ding, M. et al., Biochem. Biophys. Res. Comm. 202(1):549-555, "Cloning and analysis of MAGE-1-related genes".
Townsend et al., "The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined With Short Synthetic Peptides", Cell 44: 959-968 (Mar. 28, 1986).
Bjorkman et al., "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens", Nature 329: 512-518 (Oct. 8, 1987).
Van der Bruggen et al., "A Gene Encoding an Antigenic Recognized by Cytolytic T Lymphocytes on a Human Melanoma", Science 254: 1643-1647 (1991).
Traversari et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E", J. Exp. Med 176: 1453-1457 (Nov. 1992).
Celis et al., "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes", Proc. Natl. Acad. Sci. USA 91: 2105-2109 (Mar. 1994).
Coulie et al., "A New Gene Coding For a Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas", J. Exp. Med. 180: 35-42 (Jul., 1994) (Not Prior Art).
Engelhard et al., "Structure of Peptides Associated with Class I and Class II MHC Molecules", Ann. Rev. Immunol. 12: 181-207 (1994).
Ruppert et al., "Prominent Role of Secondary Anchnor Residues in Peptide Binding to HLA-A2.1 Molecules", Cell 74: 929-937 (Sep. 10, 1993).
DeSmet et al., "Sequence and expression pattern of the human MAGE-2 gene", Immunogenetics 39: 121-129 (1994).
Boon-Falleur Thierry
Kast W. M.
Melief Cornelis J. M.
van der Bruggen Pierre
Visseren M. J. W.
Cunningham Thomas M.
University of Leiden
LandOfFree
Isolated tumor rejection antigen precursor MAGE-2 derived peptid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated tumor rejection antigen precursor MAGE-2 derived peptid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated tumor rejection antigen precursor MAGE-2 derived peptid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321601